Amarillo, Texas, August 17, 2009 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Manfred Beilharz, Chairman of the Department of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences at the University of Western Australia was recently interviewed by Graham Mabury on 6PR Nightline, a radio program in Australia. Dr. Beilharz is a co-investigator of the ongoing Phase 2, 200-subject clinical trial that is testing the efficacy of ABI’s oral interferon alpha in preventing influenza and winter colds.
Dr. Beilharz discusses the development history and mechanism of action of oral interferon as well as the ongoing Phase 2 clinical trial in Perth, Australia in which 200 healthy volunteers are taking oral interferon lozenges provided by Amarillo Biosciences, Inc. or a matching placebo once a day for 16 weeks as a prevention for winter colds and influenza. The interview can be heard at: http://www.amarbio.com/index.php?option=com_content&view=article&id=85&Itemid=100013
About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 7% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. In its 25-year history, the Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web site at http://www.amarbio.com/.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” and “Item 7A. Qualitative and Quantitative Disclosures About Market Risk” of the Company’s Form 10-K for the fiscal year ended December 31, 2008. --END--